Stifel Nicolaus Forecasts Strong Price Appreciation for AbCellera Biologics (NASDAQ:ABCL) Stock

AbCellera Biologics (NASDAQ:ABCL) had its target price lifted by research analysts at Stifel Nicolaus from $9.00 to $14.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus‘s price target indicates a potential upside of 12.00% from the company’s previous close.

A number of other brokerages also recently issued reports on ABCL. The Goldman Sachs Group initiated coverage on AbCellera Biologics in a report on Thursday, September 24th. They set a “neutral” rating and a $13.00 price target for the company. Jefferies Financial Group started coverage on AbCellera Biologics in a research report on Friday, October 30th. They set a “buy” rating and a $21.00 target price on the stock. Cantor Fitzgerald boosted their target price on AbCellera Biologics from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Wall Street Zen raised AbCellera Biologics from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Finally, UBS Group began coverage on shares of AbCellera Biologics in a research note on Monday, October 12th. They issued a “buy” rating and a $18.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.33.

AbCellera Biologics Trading Up 5.2%

AbCellera Biologics stock opened at $12.50 on Tuesday. The stock has a market cap of $3.83 billion, a P/E ratio of -23.15 and a beta of 1.59. The company has a fifty day simple moving average of $12.30 and a 200-day simple moving average of $7.08. AbCellera Biologics has a 12-month low of $2.74 and a 12-month high of $15.02.

AbCellera Biologics (NASDAQ:ABCL) last issued its earnings results on Monday, November 9th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. The firm had revenue of $10.64 million during the quarter, compared to the consensus estimate of $8.41 million. AbCellera Biologics had a negative net margin of 248.83% and a negative return on equity of 17.49%. During the same quarter in the previous year, the firm posted ($0.19) earnings per share. As a group, sell-side analysts forecast that AbCellera Biologics will post -0.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AbCellera Biologics

Large investors have recently bought and sold shares of the stock. HighTower Advisors LLC increased its position in shares of AbCellera Biologics by 24.7% during the third quarter. HighTower Advisors LLC now owns 134,631 shares of the company’s stock worth $1,964,000 after purchasing an additional 26,698 shares in the last quarter. Bessemer Group Inc. purchased a new stake in shares of AbCellera Biologics in the 3rd quarter valued at about $380,000. Allworth Financial LP boosted its position in shares of AbCellera Biologics by 35.3% in the 3rd quarter. Allworth Financial LP now owns 15,748 shares of the company’s stock valued at $230,000 after purchasing an additional 4,105 shares during the period. Pictet Asset Management Holding SA acquired a new stake in shares of AbCellera Biologics in the 3rd quarter valued at about $4,089,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of AbCellera Biologics in the 3rd quarter valued at about $242,000. Institutional investors and hedge funds own 61.42% of the company’s stock.

Trending Headlines about AbCellera Biologics

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: AbCellera reported a Q3 loss of $0.13 per share, narrower than the roughly $0.17–$0.18 loss analysts expected and the $0.19 loss a year earlier. Revenue of $10.64 million also topped the $8.41 million consensus estimate, giving investors evidence of better-than-expected results. Zacks Q3 earnings report
• Negative Sentiment: The earnings beat does not yet resolve profitability concerns: ABCL still reported a quarterly loss, with a negative net margin and negative return on equity. Continued losses could temper the positive reaction to the revenue and EPS surprise. MarketBeat earnings report

About AbCellera Biologics

AbCellera Biologics Inc is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease.

The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.

Founded in 2012, AbCellera has collaborated with global partners, including Eli Lilly, on antibody treatments for COVID-19.